• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

AstraZeneca

1,629.50 SEK+1.68 %15.7. klo 18.29
Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.68 %
-3.81 %
-12.51 %
-7.68 %
-4.34 %
+18.25 %
+17.31 %
+57.14 %
+8,816.31 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.53T SEK
Turnover
812.78M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.7.
2026

Interim report Q2'26

30.10.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release20.11.2025 klo 09.00

AstraZeneca: Koselugo (selumetinib) approved in the US

AstraZeneca
Regulatory press release14.07.2025 klo 09.00

AstraZeneca: Baxdrostat met primary endpt in BaxHTN PhIII trial

AstraZeneca
Regulatory press release24.06.2025 klo 09.00

AstraZeneca: Datroway approved in US for EGFRm lung cancer

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release28.02.2025 klo 15.06

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

AstraZeneca
Regulatory press release06.02.2025 klo 09.00

AstraZeneca: Final Results

AstraZeneca
Regulatory press release07.10.2024 klo 11.30

AstraZeneca licenses lipid lowering Lp(a) asset

AstraZeneca
Regulatory press release07.03.2024 klo 13.00

AstraZeneca: Notice of AGM

AstraZeneca
Regulatory press release21.02.2024 klo 09.00

AstraZeneca: Filing of Form 20-F with SEC

AstraZeneca
Regulatory press release09.11.2023 klo 09.00

AstraZeneca: 9M and Q3 2023 results

AstraZeneca
Press release25.07.2022 klo 09.11

AstraZeneca: Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

AstraZeneca
Press release25.07.2022 klo 09.06

AstraZeneca: Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

AstraZeneca
Press release25.07.2022 klo 09.01

AstraZeneca: Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

AstraZeneca
Regulatory press release19.07.2022 klo 09.01

AstraZeneca: Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

AstraZeneca
Press release16.05.2022 klo 09.00

AstraZeneca: PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

AstraZeneca
Regulatory press release14.12.2020 klo 11.00

AstraZeneca to acquire Alexion Pharmaceuticals Inc

AstraZeneca
Regulatory press release03.12.2019 klo 11.00

AstraZeneca divests Seroquel rights: US and Canada

AstraZeneca
Regulatory press release23.10.2018 klo 12.00

AstraZeneca Extends Innate Pharma Collaboration

AstraZeneca
Regulatory press release01.10.2018 klo 12.00

AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed

AstraZeneca
Regulatory press release24.09.2018 klo 12.00

Farxiga gets positive result in DECLARE-TIMI 58

AstraZeneca